Trials / Recruiting
RecruitingNCT07004296
A Study of HDM2005 in Patients With Advanced Solid Tumor
A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HDM2005 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study evaluating the efficacy, safety, and pharmacokinetics ofHDM2005 in participants with metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HDM2005 | HDM2005 will be administered via IV infusion. |
Timeline
- Start date
- 2025-05-29
- Primary completion
- 2027-07-01
- Completion
- 2027-12-01
- First posted
- 2025-06-04
- Last updated
- 2025-06-08
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07004296. Inclusion in this directory is not an endorsement.